{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T23:28:49Z","timestamp":1761780529638,"version":"build-2065373602"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":281,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Increased risk of cancer has been reported in SSc patients; however, the magnitude of this risk seems to vary with SSc-specific autoantibody profile. We aimed to review cancer risk in SSc patients by autoantibody subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed literature related to cancer in SSc patients from January 1980 to December 2023 using PubMed, Embase, Scopus, and Cochrane Library. We performed a meta-analysis comparing cancer risk in SSc patients with ACA, anti-RNAP III antibody, and anti-Scl70 antibody. The search was conducted on 1 December 2023 and updated on 30 December 2023. Eligible studies were required to (1) include participants \u226518\u2009years who fulfilled the 2013 ACR\/EULAR, 1980 ACR modified, or LeRoy and Medsger classification criteria, (2) report cancer incidence with SSc-specific autoantibody, and (3) analyse the relationship between SSc-specific autoantibodies and cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two eligible studies were included and underwent meta-analysis. Anti-RNAP III positivity was associated with a significantly increased cancer risk in SSc patients (pooled relative risk (RR) 1.48; 95% CI 1.16\u20131.80), compared with anti-RNAP III-negative patients. While the presence of ACA was associated with a lower cancer risk (pooled RR 0.78; 95% CI 0.60\u20130.96) and may serve as an indicator for solely SSc, specifically limited systemic scleroderma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our meta-analysis showed that anti-RNAP III-positive SSc patients had a 48% higher risk of developing cancer compared with anti-RNAP III-negative SSc patients. Therefore, physicians should be aware of this elevated risk. Rigorous screening for malignancy by age-appropriate and relevant family history is recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkaf115","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:34:29Z","timestamp":1759750469000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of malignancy risk in patients with SSc by autoantibody profile: a systematic review with meta-analysis"],"prefix":"10.1093","volume":"9","author":[{"given":"Kamonwan","family":"Towachiraporn","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Srinakharinwirot University , Bangkok,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woramate","family":"Sanyanusin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Srinakharinwirot University , Bangkok,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salinee","family":"Rojhirunsakool","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Srinakharinwirot University , Bangkok,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon P","family":"Smith","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4573-4839","authenticated-orcid":false,"given":"Chotinij","family":"Lertphanichkul","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Srinakharinwirot University , Bangkok,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2025102919265339400_rkaf115-B1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Signos cl\u00ednicos y caracter\u00edsticas histol\u00f3gicas en pacientes con esclerodermia","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"2025102919265339400_rkaf115-B2","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025102919265339400_rkaf115-B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum Dis Clin"},{"key":"2025102919265339400_rkaf115-B4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025102919265339400_rkaf115-B5","doi-asserted-by":"crossref","first-page":"103167","DOI":"10.1016\/j.autrev.2022.103167","article-title":"Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: data from the Spanish Scleroderma Registry (RESCLE)","volume":"21","author":"Carbonell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025102919265339400_rkaf115-B6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/rheumatology\/ken442","article-title":"Reports of abnormal cervical cancer screening tests in systemic sclerosis","volume":"48","author":"Bernatsky","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2025102919265339400_rkaf115-B7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"2025102919265339400_rkaf115-B8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025102919265339400_rkaf115-B9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025102919265339400_rkaf115-B10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2017.05.023","article-title":"Auto-antibodies and cancer in systemic sclerosis","volume":"16","author":"Boonstra","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025102919265339400_rkaf115-B11","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025102919265339400_rkaf115-B12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s100670050029","article-title":"Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis","volume":"19","author":"Higuchi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"2025102919265339400_rkaf115-B13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00296-008-0540-9","article-title":"Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study","volume":"28","author":"Lu","year":"2008","journal-title":"Rheumatol Int"},{"volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2022","author":"Higgins","key":"2025102919265339400_rkaf115-B14"},{"key":"2025102919265339400_rkaf115-B15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"author":"Risk Of Bias In Non-randomized Studies\u2014of Exposure (ROBINS-E)","key":"2025102919265339400_rkaf115-B16"},{"key":"2025102919265339400_rkaf115-B17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/03009740802642062","article-title":"Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre","volume":"38","author":"Kang","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"2025102919265339400_rkaf115-B18","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025102919265339400_rkaf115-B19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/1346-8138.12827","article-title":"Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis","volume":"42","author":"Saigusa","year":"2015","journal-title":"J Dermatol"},{"key":"2025102919265339400_rkaf115-B20","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10067-016-3288-8","article-title":"Risk factors for malignancy in systemic sclerosis patients","volume":"35","author":"Ka\u015fifo\u011flu","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025102919265339400_rkaf115-B21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/1756-185X.13311","article-title":"Systemic sclerosis and malignancy","volume":"21","author":"Sargin","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2025102919265339400_rkaf115-B22","first-page":"41","article-title":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain","volume":"37","author":"Callejas-Moraga","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025102919265339400_rkaf115-B23","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/acr.24076","article-title":"Incidence, risk factors, and outcomes of cancer in systemic sclerosis","volume":"72","author":"Morrisroe","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025102919265339400_rkaf115-B24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5114\/ada.2020.102107","article-title":"Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis","volume":"37","author":"Wielosz","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"2025102919265339400_rkaf115-B25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjd.19549","article-title":"Evaluation of malignancy risk in scleroderma by antibody profile","volume":"184","author":"Lertphanichkul","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025102919265339400_rkaf115-B26","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/rheumatology\/keab735","article-title":"Association between autoantibodies in systemic sclerosis and cancer in a national registry","volume":"61","author":"Hoa","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025102919265339400_rkaf115-B27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00393-022-01219-z","article-title":"Cancer in systemic sclerosis: association between antibodies and malignancy","volume":"81","author":"Sieiro Santos","year":"2022","journal-title":"Z Rheumatol"},{"key":"2025102919265339400_rkaf115-B28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/2397198318766825","article-title":"Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: longitudinal data from the Canadian Scleroderma Research Group","volume":"3","author":"Sakr","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"2025102919265339400_rkaf115-B29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.autrev.2012.06.003","article-title":"Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature","volume":"12","author":"Colaci","year":"2013","journal-title":"Autoimmun Rev"},{"key":"2025102919265339400_rkaf115-B30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","article-title":"Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature","volume":"13","author":"Colaci","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025102919265339400_rkaf115-B31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10067-007-0546-9","article-title":"Associations of breast cancer development in patients with systemic sclerosis: an exploratory study","volume":"26","author":"Derk","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2025102919265339400_rkaf115-B32","first-page":"1994","article-title":"Autoantibodies in patients with systemic sclerosis and cancer: a case-control study","volume":"30","author":"Derk","year":"2003","journal-title":"J Rheumatol"},{"key":"2025102919265339400_rkaf115-B33","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025102919265339400_rkaf115-B34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025102919265339400_rkaf115-B35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/SMJ.0b013e31815838ce","article-title":"Systemic sclerosis and malignancy: a review of the literature","volume":"101","author":"Wooten","year":"2008","journal-title":"South Med J"},{"key":"2025102919265339400_rkaf115-B36","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025102919265339400_rkaf115-B37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"2025102919265339400_rkaf115-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1313.001","article-title":"Posttranslational modifications of self-antigens","volume":"1050","author":"Doyle","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2025102919265339400_rkaf115-B39","doi-asserted-by":"crossref","first-page":"22321","DOI":"10.1074\/jbc.274.32.22321","article-title":"Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins","volume":"274","author":"Mamula","year":"1999","journal-title":"J Biol Chem"},{"key":"2025102919265339400_rkaf115-B40","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3389\/fimmu.2018.03112","article-title":"Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors","volume":"9","author":"Maria","year":"2018","journal-title":"Front Immunol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkaf115\/64569857\/rkaf115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/4\/rkaf115\/64569857\/rkaf115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/4\/rkaf115\/64569857\/rkaf115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T23:26:59Z","timestamp":1761780419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaf115\/8279668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,13]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaf115","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rkaf115"}}